Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCT00845507 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication exenatide can help reduce weight gain in obese adults who are taking olanzapine.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 54 people

Who can join Ages 18–55 · all sexes

Timeline Started 2008-12 · est. completion 2015-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00845507 ↗

Description as written by the study sponsor.

The purpose of this research study is to test the safety and efficacy (how well it works) of exenatide as a treatment for weight gain associated with olanzapine in obese adults with Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder Exenatide has been approved by the FDA for the treatment of Type 2 diabetes. It has not been approved for the treatment of weight gain associated with olanzapine in obese adults with bipolar disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder

Treatments tested

Exenatide also known as Exenatide (Byeta) Drug

The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
Placebo Drug

Placebo: Sterile solution in equivalent doses as Exenatide

Main thing measured	Change in Weight From Baseline to Endpoint.
Sponsor	University of Cincinnati
Conditions studied	Weight Gain
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00845507 ↗